Organon & Co. (NYSE:OGN) Receives $20.80 Consensus Target Price from Analysts

Organon & Co. (NYSE:OGN) has been given a consensus rating of “Hold” by the seven analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $20.80.

A number of equities analysts have recently weighed in on OGN shares. TD Cowen upgraded Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Morgan Stanley cut their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday, February 14th. Finally, Barclays lowered their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 14th.

Organon & Co. Price Performance

NYSE:OGN opened at $14.97 on Tuesday. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The firm has a market cap of $3.86 billion, a P/E ratio of 4.49, a PEG ratio of 0.90 and a beta of 0.76. The business’s 50-day moving average price is $15.46 and its 200 day moving average price is $16.78.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. As a group, sell-side analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were given a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 7.48%. The ex-dividend date of this dividend was Monday, February 24th. Organon & Co.’s dividend payout ratio is currently 33.63%.

Institutional Investors Weigh In On Organon & Co.

A number of institutional investors have recently added to or reduced their stakes in the company. Siemens Fonds Invest GmbH acquired a new stake in Organon & Co. during the fourth quarter worth about $8,998,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Organon & Co. during the fourth quarter worth about $11,892,000. Leigh Baldwin & CO. LLC bought a new position in Organon & Co. during the fourth quarter worth about $235,000. Public Employees Retirement System of Ohio lifted its stake in Organon & Co. by 26.4% during the fourth quarter. Public Employees Retirement System of Ohio now owns 118,128 shares of the company’s stock worth $1,762,000 after purchasing an additional 24,696 shares during the period. Finally, Vise Technologies Inc. bought a new position in Organon & Co. during the fourth quarter worth about $238,000. 77.43% of the stock is owned by institutional investors and hedge funds.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.